Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harrow Inc HROW

Healthcare Biotechnology
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America... see more

Recent & Breaking News (NDAQ:HROW)

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

Business Wire February 15, 2024

Harrow Announces New Appointments to its Board of Directors

Business Wire January 29, 2024

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Business Wire January 11, 2024

Melt Pharmaceuticals Provides Corporate Update

Business Wire January 3, 2024

Harrow Partners with Leading Healthcare Market Access Technology Platforms

Business Wire January 3, 2024

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Business Wire November 29, 2023

Harrow to Present at Two Investor Conferences in November

Business Wire November 20, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Harrow, Inc. (HROW)

ACCESS Newswire November 15, 2023

Harrow Announces Third Quarter 2023 Financial Results

Business Wire November 13, 2023

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

Business Wire October 30, 2023

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Business Wire October 24, 2023

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

Business Wire September 29, 2023

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

Business Wire September 26, 2023

Harrow Announces Second Quarter 2023 Financial Results

Business Wire August 9, 2023

Harrow Launches VIGAMOX® in the U.S.

Business Wire July 31, 2023

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023

Business Wire July 26, 2023

Harrow Prices $60 Million Public Offering of Common Stock

Business Wire July 19, 2023

Harrow Acquires Santen's Branded Ophthalmic Portfolio

Business Wire July 18, 2023

Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

Business Wire July 18, 2023

Harrow Announces Proposed Public Offering of Common Stock

Business Wire July 18, 2023